JP2008528469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528469A5 JP2008528469A5 JP2007551744A JP2007551744A JP2008528469A5 JP 2008528469 A5 JP2008528469 A5 JP 2008528469A5 JP 2007551744 A JP2007551744 A JP 2007551744A JP 2007551744 A JP2007551744 A JP 2007551744A JP 2008528469 A5 JP2008528469 A5 JP 2008528469A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally
- combination according
- hydrogen
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64596305P | 2005-01-21 | 2005-01-21 | |
| PCT/GB2006/000206 WO2006077425A1 (en) | 2005-01-21 | 2006-01-20 | Combinations of pyrazole kinase inhibitors and further antitumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528469A JP2008528469A (ja) | 2008-07-31 |
| JP2008528469A5 true JP2008528469A5 (enExample) | 2009-03-12 |
Family
ID=35966985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551744A Withdrawn JP2008528469A (ja) | 2005-01-21 | 2006-01-20 | ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080161355A1 (enExample) |
| EP (1) | EP1845975A1 (enExample) |
| JP (1) | JP2008528469A (enExample) |
| KR (1) | KR20070107707A (enExample) |
| CN (1) | CN101146533A (enExample) |
| AU (1) | AU2006207322A1 (enExample) |
| BR (1) | BRPI0606319A2 (enExample) |
| CA (1) | CA2593475A1 (enExample) |
| MX (1) | MX2007008809A (enExample) |
| RU (1) | RU2007131101A (enExample) |
| WO (1) | WO2006077425A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ544756A (en) * | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| TW200533657A (en) | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| WO2006077428A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| WO2006077424A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
| CN101133088B (zh) * | 2005-03-03 | 2011-04-13 | 三菱丽阳株式会社 | 聚合物粒子、含有它的树脂组合物、成型体 |
| EP1743890A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
| US7897589B2 (en) | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1743892A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| US20090318500A1 (en) * | 2006-05-05 | 2009-12-24 | Astex Therapeutics Limited | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer |
| US20090142337A1 (en) * | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
| US20110159111A1 (en) * | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20100004243A1 (en) * | 2006-07-14 | 2010-01-07 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2049106A2 (en) * | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| FR2908409B1 (fr) * | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
| EP2070924A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
| EP2070925A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel |
| EP2070916A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| CA2738909A1 (en) * | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| CN102231984A (zh) * | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护 |
| US20100144687A1 (en) | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
| US20120100100A1 (en) * | 2009-05-13 | 2012-04-26 | Sharpless Norman E | Cyclin dependent kinase inhibitors and methods of use |
| FR2947546B1 (fr) * | 2009-07-03 | 2011-07-01 | Sanofi Aventis | Derives de pyrazoles, leur preparation et leur application en therapeutique |
| CA2776327A1 (en) | 2009-10-01 | 2011-04-07 | Janssen Pharmaceutica Nv | Proteasome inhibitors for treating cancer |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| CA2818046A1 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6 |
| PE20151280A1 (es) * | 2012-12-21 | 2015-09-12 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones |
| CN103012428A (zh) * | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
| US20140271460A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly Active Anti-Neoplastic and Anti-Proliferative Agents |
| CN105473140B (zh) | 2013-03-15 | 2018-04-10 | G1治疗公司 | 在化学疗法期间对正常细胞的瞬时保护 |
| JP2017502989A (ja) * | 2014-01-15 | 2017-01-26 | ノバルティス アーゲー | 組合せ医薬 |
| WO2015161285A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| EP3302448B1 (en) | 2015-06-04 | 2023-10-25 | Aurigene Oncology Limited | Substituted heterocyclyl derivatives as cdk inhibitors |
| US10723705B2 (en) | 2015-08-14 | 2020-07-28 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| JP6814814B2 (ja) | 2016-03-17 | 2021-01-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体 |
| AU2017315357B2 (en) | 2016-08-23 | 2022-12-01 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| IL269357B2 (en) | 2017-03-16 | 2024-10-01 | Eisai R&D Man Co Ltd | A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer |
| CN107652284B (zh) * | 2017-09-30 | 2020-01-31 | 武汉九州钰民医药科技有限公司 | 用于治疗增殖性疾病的cdk抑制剂 |
| CN107686477B (zh) * | 2017-09-30 | 2020-01-31 | 武汉九州钰民医药科技有限公司 | 作为cdk4/6抑制剂的新型化合物及其应用 |
| CA3176237A1 (en) | 2020-04-29 | 2021-11-04 | Jack Lin | Synthesis of heterocyclic compounds |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| KR102507397B1 (ko) * | 2020-09-10 | 2023-03-07 | 계명대학교 산학협력단 | 히스톤 탈아세틸화효소 억제 활성을 갖는 신규 화합물 및 이의 용도 |
| CN112755023B (zh) * | 2021-01-22 | 2023-04-25 | 湖南师范大学 | 一种新型表观遗传因子抑制剂2800z在制备肝癌药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282361A (en) * | 1978-03-16 | 1981-08-04 | Massachusetts Institute Of Technology | Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines |
| US5164196A (en) * | 1987-05-19 | 1992-11-17 | Ventech Research, Inc. | Crotoxin complex as cytotoxic agent |
| US5002755A (en) * | 1988-02-18 | 1991-03-26 | Vanderbilt University | Method of controlling nephrotoxicity of anti-tumor plaintum compounds |
| US5514665A (en) * | 1993-12-30 | 1996-05-07 | University Of British Columbia | Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans |
| US5502068A (en) * | 1995-01-31 | 1996-03-26 | Synphar Laboratories, Inc. | Cyclopropylpyrroloindole-oligopeptide anticancer agents |
| US6066738A (en) * | 1996-01-30 | 2000-05-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| EP1264820A4 (en) * | 2000-03-14 | 2004-09-15 | Fujisawa Pharmaceutical Co | amide compounds |
| US6455559B1 (en) * | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| US20050260277A1 (en) * | 2001-02-28 | 2005-11-24 | Giles Brian C | Method and formula for anti-tumor and anti-matastatic effect |
| JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| WO2002092002A2 (en) * | 2001-05-11 | 2002-11-21 | The Burnham Institute | Screening, diagnostic and therapeutic methods relating to riz |
| KR20060111716A (ko) * | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온 |
| RU2394022C2 (ru) * | 2002-03-04 | 2010-07-10 | МЕРК ЭйчДиЭйСи Рисерч, ЛЛС | Способы индукции конечной дифференцировки |
| AR041291A1 (es) * | 2002-09-19 | 2005-05-11 | Schering Corp | Imidazopiridinas como inhibidores de quinasa dependientes de ciclina |
| WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| NZ544756A (en) * | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| WO2006077424A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
| TW200745003A (en) * | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
-
2006
- 2006-01-20 JP JP2007551744A patent/JP2008528469A/ja not_active Withdrawn
- 2006-01-20 CN CNA2006800091875A patent/CN101146533A/zh active Pending
- 2006-01-20 US US11/814,455 patent/US20080161355A1/en not_active Abandoned
- 2006-01-20 CA CA002593475A patent/CA2593475A1/en not_active Abandoned
- 2006-01-20 MX MX2007008809A patent/MX2007008809A/es not_active Application Discontinuation
- 2006-01-20 AU AU2006207322A patent/AU2006207322A1/en not_active Abandoned
- 2006-01-20 BR BRPI0606319-5A patent/BRPI0606319A2/pt not_active IP Right Cessation
- 2006-01-20 KR KR1020077018887A patent/KR20070107707A/ko not_active Withdrawn
- 2006-01-20 EP EP06700799A patent/EP1845975A1/en not_active Withdrawn
- 2006-01-20 WO PCT/GB2006/000206 patent/WO2006077425A1/en not_active Ceased
- 2006-01-20 RU RU2007131101/04A patent/RU2007131101A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528469A5 (enExample) | ||
| JP2008528468A5 (enExample) | ||
| JP7696443B2 (ja) | Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類 | |
| JP6532878B2 (ja) | 組合せ医薬 | |
| CN107427516B (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2008528471A5 (enExample) | ||
| RU2020112759A (ru) | Гетероциклические соединения в качестве ингибиторов PAD | |
| RU2007131101A (ru) | Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований | |
| JP2024072291A (ja) | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 | |
| US20230338314A1 (en) | Methods for the treatment of myeloid derived suppressor cells related disorders | |
| JP2007517807A5 (enExample) | ||
| US9205091B2 (en) | Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer | |
| JP2005526794A5 (ja) | ベンズイミダゾールおよびマイトジェン活性化およびｒｈｏキナーゼ阻害剤としてのその使用 | |
| US20240197729A1 (en) | ALK-5 Inhibitors and Uses Thereof | |
| BRPI0612076A2 (pt) | modulação sinergìstica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase | |
| WO2023069727A1 (en) | Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections | |
| JP2014512362A5 (enExample) | ||
| RU2008129623A (ru) | Ингибиторы ccr9 активности | |
| CA3209512A1 (en) | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | |
| MA28930B1 (fr) | Derives pyridiniques d'indolin-2-one , leur preparation et leur application en therapeutique | |
| JP6737443B2 (ja) | 治療的処置でのＢＣＲＰ阻害剤としての使用のための４−アミノ−３−フェニルアミノ−６−フェニルピラゾロ［３，４−ｄ］ピリミジン誘導体 | |
| US20210220331A1 (en) | Inhibitors of ires-mediated protein synthesis | |
| US20240360135A1 (en) | Imidazo[1,2-b]pyridazinyl compounds and uses thereof | |
| WO2018222975A1 (en) | Methods for the treatment of cancer | |
| EA200970496A1 (ru) | Соединения 2-алкилиндазола для лечения некоторых расстройств цнс |